GlassScriptPhysician profile
Danielle Caliolio
NPI 1316511405
$2,587.29
in general payments reported to CMS, 2019-2025
31 companies · $69.86 in 2025
The $69.86 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $642 · 2022: $799 · 2023: $682 · 2024: $394 · 2025: $69.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,145.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $670.20 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $216.83 | 2023-2024 | Gemtesa, Myfembree |
| Mayne Pharma Commercial LLC | $195.17 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.55 | 2021-2024 | Xifaxan, Trulance |
| Exeltis, USA INC. | $132.92 | 2021-2025 | Slynd |
| Pfizer INC. | $118.49 | 2021-2024 | |
| Novo Nordisk INC | $99.03 | 2022-2025 | Wegovy |
| Therapeuticsmd, INC. | $93.69 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.76 | 2021 | |
| Myovant Sciences INC. | $85.13 | 2022 | |
| Agile Therapeutics, INC. | $71.26 | 2021-2024 | Twirla |
| Urovant Sciences INC | $57.60 | 2022 | |
| Sage Therapeutics, LLC | $57.43 | 2024 | |
| Evofem Biosciences, INC. | $54.79 | 2022-2024 | |
| Millicent US INC | $48.20 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $44.27 | 2021-2024 | Trintellix |
| Dysis Medical, INC. | $43.43 | 2022 | |
| Mycovia Pharmaceuticals, INC. | $41.62 | 2023 | Vivjoa |
| Hologic Sales and Service, LLC | $40.65 | 2021 | |
| Astellas Pharma US INC | $33.44 | 2023-2024 | Veozah |
| Lilly USA, LLC | $33.15 | 2024 | Zepbound |
| Exact Sciences Corporation | $31.77 | 2024 | Cologuard Collection Kit |
| Qol Medical, LLC | $28.50 | 2021 | |
| Avion Pharmaceuticals | $28.20 | 2022-2023 | Balcoltra |
| Currax Pharmaceuticals LLC | $26.67 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.99 | 2021 | |
| Becton, Dickinson and Company | $19.87 | 2021 | |
| Lundbeck LLC | $17.00 | 2024 | Vyepti |
| Ibsa Pharma INC. | $14.30 | 2023 | Tirosint, Licart |
| Biohaven Pharmaceutical Holding Company LTD. | $13.85 | 2022 | |
| Ironwood Pharmaceuticals, INC | $12.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Caliolio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.